Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Neuronetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STIM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: STIM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: STIM exceeded the US Medical Equipment industry which returned 33.8% over the past year.
Return vs Market: STIM exceeded the US Market which returned 51.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Neuronetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StWhat Type Of Shareholders Make Up Neuronetics, Inc.'s (NASDAQ:STIM) Share Registry?
1 month ago | Simply Wall StCan You Imagine How Elated Neuronetics' (NASDAQ:STIM) Shareholders Feel About Its 980% Share Price Gain?
2 months ago | Simply Wall StThis Insider Has Just Sold Shares In Neuronetics, Inc. (NASDAQ:STIM)
Is Neuronetics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate STIM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate STIM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: STIM is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: STIM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate STIM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: STIM is good value based on its PB Ratio (3.5x) compared to the US Medical Equipment industry average (4.7x).
How is Neuronetics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STIM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STIM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STIM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STIM's revenue (24.2% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: STIM's revenue (24.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STIM's Return on Equity is forecast to be high in 3 years time
How has Neuronetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STIM is currently unprofitable.
Growing Profit Margin: STIM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STIM is unprofitable, and losses have increased over the past 5 years at a rate of 17.5% per year.
Accelerating Growth: Unable to compare STIM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STIM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.5%).
Return on Equity
High ROE: STIM has a negative Return on Equity (-22.28%), as it is currently unprofitable.
How is Neuronetics's financial position?
Financial Position Analysis
Short Term Liabilities: STIM's short term assets ($138.9M) exceed its short term liabilities ($10.9M).
Long Term Liabilities: STIM's short term assets ($138.9M) exceed its long term liabilities ($39.4M).
Debt to Equity History and Analysis
Debt Level: STIM's debt to equity ratio (34.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if STIM's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STIM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: STIM has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26.7% each year
What is Neuronetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate STIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STIM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STIM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STIM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STIM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Keith Sullivan (62 yo)
Mr. Keith J. Sullivan has been President, Chief Executive Officer and Director of Neuronetics, Inc. since July 14, 2020. Mr. Sullivan has been a Director of Venus Concept Inc. (formerly known as Restoratio...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD3.89M) is above average for companies of similar size in the US market ($USD1.73M).
Compensation vs Earnings: Insufficient data to compare Keith's compensation with company performance.
Experienced Management: STIM's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: STIM's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: STIM insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.4%.
Neuronetics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Neuronetics, Inc.
- Ticker: STIM
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$356.154m
- Shares outstanding: 25.73m
- Website: https://www.neurostar.com
Number of Employees
- Neuronetics, Inc.
- 3222 Phoenixville Pike
- United States
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offer...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 22:54|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.